recombinant human serum albumin-interferon-alpha-2a fusion protein (Qilu Pharmaceutical)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namerecombinant human serum albumin-interferon-alpha-2a fusion protein (Qilu Pharmaceutical)
Drug Alias NamerHSA-IFN alpha-2a (Qilu Pharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterferon alpha 2 ligand
TargetsInterferon alpha-2
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Biotechnology, Academy Of Military Medical Sciences. Pla Of ChinaQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A